Clinical Trials Logo

Esophagogastric Adenocarcinoma clinical trials

View clinical trials related to Esophagogastric Adenocarcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05504720 Active, not recruiting - Clinical trials for Esophagogastric Adenocarcinoma

Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma

Start date: February 13, 2023
Phase: Phase 2
Study type: Interventional

The study is an open-label, single arm, multicenter phase II trial investigating the clinical activity of a perioperative therapy consisting of a combination of pembrolizumab, trastuzumab and FLOT, followed by pembrolizumab plus trastuzumab alone for a maximum systemic treatment duration of one year in patients with Her-2 positive localized esophagogastric adenocarcinoma.

NCT ID: NCT05268510 Active, not recruiting - Clinical trials for Esophagogastric Adenocarcinoma

Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma

Start date: September 15, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of a first-line therapy consisting of induction chemotherapy plus pembrolizumab (12 weeks of mod. FOLFOX-6 plus pembrolizumab or 12 weeks of CAPOX plus pembrolizumab) followed by pembrolizumab plus olaparib.